Concepts (76)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 3 | 2019 | 36 | 0.490 |
Why?
|
| Endometrial Neoplasms | 3 | 2022 | 9 | 0.380 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2022 | 51 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 105 | 0.330 |
Why?
|
| Gynecology | 1 | 2010 | 5 | 0.320 |
Why?
|
| Medical Oncology | 1 | 2010 | 23 | 0.320 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2010 | 68 | 0.300 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 69 | 0.240 |
Why?
|
| Mutation | 2 | 2022 | 175 | 0.200 |
Why?
|
| Paclitaxel | 2 | 2021 | 25 | 0.180 |
Why?
|
| Genital Neoplasms, Female | 1 | 2020 | 4 | 0.160 |
Why?
|
| Female | 9 | 2022 | 6974 | 0.150 |
Why?
|
| Phthalazines | 1 | 2019 | 4 | 0.150 |
Why?
|
| Folic Acid Deficiency | 1 | 2019 | 6 | 0.150 |
Why?
|
| Piperazines | 1 | 2019 | 41 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 165 | 0.140 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2018 | 2 | 0.140 |
Why?
|
| Hydrazines | 1 | 2018 | 4 | 0.140 |
Why?
|
| Peritoneal Neoplasms | 1 | 2018 | 5 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2018 | 6 | 0.140 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 99 | 0.140 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 168 | 0.140 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2016 | 7 | 0.120 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 59 | 0.120 |
Why?
|
| Humans | 9 | 2022 | 12240 | 0.120 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 546 | 0.100 |
Why?
|
| Bevacizumab | 2 | 2022 | 8 | 0.090 |
Why?
|
| Sirolimus | 2 | 2022 | 13 | 0.090 |
Why?
|
| Cervix Uteri | 1 | 2011 | 9 | 0.090 |
Why?
|
| Vagina | 1 | 2011 | 14 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2011 | 16 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 40 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 23 | 0.080 |
Why?
|
| Middle Aged | 4 | 2019 | 4043 | 0.060 |
Why?
|
| Adult | 4 | 2018 | 3557 | 0.060 |
Why?
|
| Vulvar Diseases | 1 | 2005 | 2 | 0.060 |
Why?
|
| Granuloma | 1 | 2005 | 11 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2022 | 171 | 0.040 |
Why?
|
| Epothilones | 1 | 2021 | 2 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 9 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2021 | 12 | 0.040 |
Why?
|
| Carboplatin | 1 | 2021 | 11 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2021 | 10 | 0.040 |
Why?
|
| Survival Rate | 1 | 2021 | 152 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2021 | 1478 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 128 | 0.040 |
Why?
|
| Aged | 3 | 2018 | 4000 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 2152 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2020 | 31 | 0.040 |
Why?
|
| Folic Acid | 1 | 2019 | 15 | 0.040 |
Why?
|
| Quality of Life | 1 | 2020 | 261 | 0.030 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2016 | 3 | 0.030 |
Why?
|
| DNA Mismatch Repair | 1 | 2016 | 3 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 4 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 6 | 0.030 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2016 | 6 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2016 | 7 | 0.030 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2016 | 4 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2016 | 29 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 28 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 43 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 151 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2011 | 1467 | 0.030 |
Why?
|
| Vaginal Smears | 1 | 2011 | 5 | 0.020 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2011 | 2 | 0.020 |
Why?
|
| Colposcopy | 1 | 2011 | 3 | 0.020 |
Why?
|
| Dyspareunia | 1 | 2005 | 2 | 0.010 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2005 | 8 | 0.010 |
Why?
|
| Recurrence | 1 | 2005 | 126 | 0.010 |
Why?
|
| Analgesics | 1 | 2005 | 48 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2005 | 186 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 118 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2005 | 211 | 0.010 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2005 | 142 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 726 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2005 | 827 | 0.010 |
Why?
|